Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 346 AL 360

ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease

Stone DJ, Molony C, Suver C, Schadt EE, Potter WZ.

Pharmacogenomics J. 2010 Jun;10(3):161-4. doi: 10.1038/tpj.2009.58. Epub 2009 Dec 8.

The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy

Sinem F, Dildar K, Gökhan E, Melda B, Orhan Y, Filiz M.

Curr Alzheimer Res. 2010 Aug;7(5):463-9. doi: 10.2174/156720510791383822.

[Pathobiology of Alzheimer's disease and biomarker development]

Arai H, Okamura N, Waragai M, Furukawa K, Yanai K, Kudo Y.

Nihon Yakurigaku Zasshi. 2010 Jan;135(1):3-7. doi: 10.1254/fpj.135.3.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

Mattsson N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2010 May;48(5):603-7. doi: 10.1515/CCLM.2010.131.

Impact of the CD40-CD40L dyad in Alzheimer's disease

Giunta B, Rezai-Zadeh K, Tan J.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):149-55. doi: 10.2174/187152710791012099.

Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

Krautwald M, Münch G.

Exp Gerontol. 2010 Oct;45(10):744-51. doi: 10.1016/j.exger.2010.03.001. Epub 2010 Mar 6.

Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible

Reiman EM, Langbaum JB, Tariot PN.

Biomark Med. 2010 Feb;4(1):3-14. doi: 10.2217/bmm.09.91.

Biochemical markers in Alzheimer's disease clinical trials

Zetterberg H, Mattsson N, Shaw LM, Blennow K.

Biomark Med. 2010 Feb;4(1):91-8. doi: 10.2217/bmm.09.80.

Cerebrospinal fluid proteins in the diagnosis of Alzheimer's disease

Papaliagkas VT, Tsolaki M, Anogianakis G.

Recent Pat CNS Drug Discov. 2010 Jun;5(2):172-8. doi: 10.2174/157488910791213194.

Integrating ADNI results into Alzheimer's disease drug development programs

Cummings JL.

Neurobiol Aging. 2010 Aug;31(8):1481-92. doi: 10.1016/j.neurobiolaging.2010.03.016. Epub 2010 May 5.

Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development

Arai H, Okamura N, Furukawa K, Kudo Y.

Tohoku J Exp Med. 2010 Jun;221(2):87-95. doi: 10.1620/tjem.221.87.

Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers

Serrano-Pozo A, Vega GL, Lütjohann D, Locascio JJ, Tennis MK, Deng A, Atri A, Hyman BT, Irizarry MC, Growdon JH.

Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):220-6. doi: 10.1097/WAD.0b013e3181d61fea.

Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment

Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1443-51, 1451.e1. doi: 10.1016/j.neurobiolaging.2010.04.036. Epub 2010 Jun 11.

Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?

Mielke MM, Lyketsos CG.

Neuromolecular Med. 2010 Dec;12(4):331-40. doi: 10.1007/s12017-010-8121-y. Epub 2010 Jun 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias